S. Duvert‐Lehembre

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

P. Joly, Maud Maho‐Vaillant, C. Prost‐Squarcioni et al. · The Lancet · 2017 · 586 citations

Ritux 3, Pharmacology, Pharmacotherapy +2

Incidence and Mortality of Bullous Pemphigoid in France

P. Joly, Sophie Baricault, A. Sparsa et al. · Journal of Investigative Dermatology · 2012 · 341 citations

Zoonotic Disease, Epidemiology, Parasitology +1

Prevalence and Clinical Significance of Anti–Laminin 332 Autoantibodies Detected by a Novel Enzyme-Linked Immunosorbent Assay in Mucous Membrane Pemphigoid

Philippe Bernard, Frank Antonicelli, Christophe Bédane et al. · JAMA Dermatology · 2013 · 100 citations

Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect

D.M. Chen, Adefowope Odueyungbo, Eva Csinady et al. · British Journal of Dermatology · 2019 · 91 citations · Full text

Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population

Marthe Plaquevent, F. Tétart, L. Fardet et al. · Journal of Investigative Dermatology · 2018 · 83 citations · Full text

French General Population, Higher Frequency, Bullous Pemphigoid Patients +2